Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Operating Leases (2019 - 2025)

Legend Biotech filings provide 7 years of Operating Leases readings, the most recent being $87.2 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 95.52% to $87.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.2 million, a 95.52% increase, with the full-year FY2025 number at $87.2 million, up 95.52% from a year prior.
  • Operating Leases hit $87.2 million in Q4 2025 for Legend Biotech, down from $88.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $88.1 million in Q3 2025 to a low of $2.5 million in Q4 2021.
  • Median Operating Leases over the past 5 years was $44.5 million (2023), compared with a mean of $48.5 million.
  • Biggest five-year swings in Operating Leases: fell 25.76% in 2021 and later skyrocketed 842.57% in 2022.
  • Legend Biotech's Operating Leases stood at $2.5 million in 2021, then skyrocketed by 842.57% to $23.6 million in 2022, then surged by 87.14% to $44.2 million in 2023, then rose by 0.98% to $44.6 million in 2024, then skyrocketed by 95.52% to $87.2 million in 2025.
  • The last three reported values for Operating Leases were $87.2 million (Q4 2025), $88.1 million (Q3 2025), and $71.7 million (Q2 2025) per Business Quant data.